Peanut Oral Immunotherapy Effective for Children Under 12 Months
Medically reviewed by Drugs.com.
By Elana Gotkine HealthDay Reporter
MONDAY, Aug. 14, 2023 -- Peanut oral immunotherapy (OIT) can induce desensitization to peanuts in children younger than 12 months of age, according to research published online July 13 in the Journal of Allergy and Clinical Immunology: In Practice.
Sarah Johnson, M.D., from the Cleveland Clinic Foundation, and colleagues reviewed the safety and effectiveness of peanut OIT in 22 children younger than 12 months of age in a retrospective study. Participants were typically started at 18 mg of peanut protein, and doses were escalated every two weeks until reaching a maintenance dose of 500 mg or more.
The researchers found that maintenance was achieved in 100 percent of patients. Overall, 13, eight, and four patients reacted during in-office up-doses, at-home during the build-up phase, and at-home during the maintenance phase, respectively. One child required epinephrine; reactions self-resolved in most children. Six patients (27 percent) had no reaction. One patient discontinued OIT after reaching maintenance due to family preference. Fourteen patients qualified for and participated in specific immunoglobulin E (sIgE) testing after maintenance for six months; all had a peanut sIgE of ≤2 kU/L. Of these 14 participants who were then offered peanut oral food challenge (OFC), 11 participated in OFC and 10 had a negative OFC.
"Overall, this signals that age is a crucial factor to the success of this treatment," Johnson said in a statement. "An infant's immune system is more adaptable, allowing them to develop tolerance to peanuts with less severe reactions and fewer side effects than older children."
One author disclosed consulting work for Genentech.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted August 2023
Read this next
Peanut Consumption Starting in Infancy Provides Lasting Tolerance
THURSDAY, May 30, 2024 -- Peanut consumption starting in infancy and continuing to age 5 years provides lasting tolerance into adolescence, according to a study published in the...
Recommendations Developed to Prepare Patients for Oral Immunotherapy
FRIDAY, April 19, 2024 -- In a research article published online April 8 in the Journal of Allergy and Clinical Immunology, consensus recommendations are presented for preparing...
Penicillin Allergy Can Be Delabeled by Nonallergy Providers
TUESDAY, April 9, 2024 -- Direct oral penicillin challenges (DPCs) can be delivered to patients with penicillin allergy labels (PALs) by nonallergy health care professionals...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.